Should I buy or sell Infinity Pharmaceuticals stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Infinity Pharmaceuticals in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" INFI shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in INFI, but not buy additional shares or sell existing shares. View INFI analyst ratings or view top-rated stocks .

How were Infinity Pharmaceuticals' earnings last quarter?

Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) issued its quarterly earnings results on Tuesday, November, 2nd. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.14) by $0.02. The biotechnology company earned $0.43 million during the quarter, compared to analysts' expectations of $0.45 million. During the same quarter in the previous year, the firm earned ($0.16) EPS.

What is Adelene Q. Perkins' approval rating as Infinity Pharmaceuticals' CEO?

10 employees have rated Infinity Pharmaceuticals Chief Executive Officer Adelene Q. Perkins on Glassdoor.com . Adelene Q. Perkins has an approval rating of 100% among the company's employees. This puts Adelene Q. Perkins in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Infinity Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Infinity Pharmaceuticals investors own include Continental Resources (CLR) , Rex Energy (REXX) , Aerie Pharmaceuticals (AERI) , Gilead Sciences (GILD) , OPKO Health (OPK) , AVEO Pharmaceuticals (AVEO) , ImmunoGen (IMGN) , Inovio Pharmaceuticals (INO) , Novavax (NVAX) and Celldex Therapeutics (CLDX) .

Who are Infinity Pharmaceuticals' major shareholders?

Infinity Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Adelene Q Perkins and Bvf Partners L P/Il. View institutional ownership trends .

Infinity Pharmaceuticals Stock Price, News & Analysis (NASDAQ:INFI)

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: N/A
50-Day Range: $0.01
▼
$0.13
52-Week Range: N/A

Volume: 2.48 million shs
Average Volume: 2.58 million shs
Market Capitalization: $726,000.00

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Analyst Forecasts Earnings Headlines Insider Trades Ownership Short Interest Social Media

About Infinity Pharmaceuticals Stock (NASDAQ:INFI)

Infinity Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel medicines for people with cancer. The company's product candidate, including eganelisib (IPI-549), an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of metastatic triple negative breast cancer and urothelial cancer; and Phase 1/1b clinical trials for the treatment of solid tumors. Infinity Pharmaceuticals, Inc. has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company. Infinity Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Cambridge, Massachusetts.

December 1, 2023 | seekingalpha.com

INFIQ Infinity Pharmaceuticals, Inc.

October 16, 2023 | businesswire.com

INFI DEADLINE TODAY: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Infinity Pharmaceuticals, Inc. Investors to Secure Counsel Before Important October 16 Deadline in Securities ...

December 5, 2023 | DTI Trader (Ad)

All the trading advice you’ve ever received boils down to this

All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.

October 16, 2023 | barrons.com

FINAL DEADLINE TODAY: The Schall Law Firm Encourages Investors in Infinity Pharmaceuticals, Inc. with Losses of $500,000 to Contact the Firm

October 15, 2023 | stockhouse.com

Infinity Ongoing Deadline Alert

October 14, 2023 | bloomberg.com

Deadline Alert: Bronstein, Gewirtz & Grossman LLC Announces that Infinity Pharmaceuticals, Inc. (INFI) Investors Have Opportuni

October 10, 2023 | finance.yahoo.com

Infinity Pharmaceuticals, Inc. (INFIQ)

October 9, 2023 | barrons.com

Bronstein, Gewirtz & Grossman LLC Notifies Infinity Pharmaceuticals, Inc. (INFI) Investors of Class Action and to Actively Participate!

December 5, 2023 | DTI Trader (Ad)

All the trading advice you’ve ever received boils down to this

October 2, 2023 | bizjournals.com

Gutted Cambridge biotech declares bankruptcy after failed merger, layoffs

October 1, 2023 | markets.businessinsider.com

Infinity Investor Shareholder Alert

September 29, 2023 | msn.com

Infinity Pharmaceuticals reportedly files for Chapter 11

September 22, 2023 | finanznachrichten.de

Faron Pharmaceuticals Oy: Faron Pharmaceuticals Announces Board Changes

September 18, 2023 | stockhouse.com

INVESTOR ACTION REMINDER: The Schall Law Firm Encourages Investors in Infinity Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

September 16, 2023 | prnewswire.com

INFINITY DEADLINE ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Infinity To Contact Him Directly To Discuss Their Options

September 16, 2023 | markets.businessinsider.com

ROSEN, A TOP RANKED LAW FIRM, Encourages Infinity Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - INFI

September 15, 2023 | stockhouse.com

INVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in Infinity Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

September 14, 2023 | stockhouse.com

SHAREHOLDER ACTION NOTICE: The Schall Law Firm Encourages Investors in Infinity Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

September 13, 2023 | gurufocus.com

Director Adelene Perkins Sells 410,196 Shares of Infinity Pharmaceuticals Inc (INFI)

September 13, 2023 | stockhouse.com

SHAREHOLDER ACTION REMINDER: The Schall Law Firm Encourages Investors in Infinity Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

September 13, 2023 | seekingalpha.com

Infinity Pharmaceuticals receives delisting determination letter from Nasdaq

September 11, 2023 | stockhouse.com

INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in Infinity Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

September 6, 2023 | benzinga.com

INFI Stockholders Should Contact Robbins LLP for Information About the Class Action Involving Infinity Pharmaceuticals, Inc.

September 6, 2023 | stockhouse.com

Infinity Shareholder Notice

September 6, 2023 | finanznachrichten.de

DEADLINE ACTION ALERT: The Schall Law Firm Encourages Investors in Infinity Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

September 5, 2023 | finance.yahoo.com

Three execs leave Infinity Pharmaceuticals after failed merger, layoffs

September 2, 2023 | stockhouse.com

SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Infinity Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

See More Headlines

Receive INFI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Infinity Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/02/2021
Today: 12/04/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: Biotechnology
Sector: Medical
Current Symbol: NASDAQ:INFI
CUSIP: 45665G30
CIK: 1113148
Web: www.infi.com
Phone: (617) 453-1000
Fax: 617-453-1001
Employees: 30
Year Founded: 2000

Profitability

EPS (Most Recent Fiscal Year): ($0.46)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-44,370,000.00
Net Margins: -1,593.93%
Pretax Margin: -1,593.93%
Return on Equity: N/A
Return on Assets: -113.02%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.65
Quick Ratio: 1.65

Sales & Book Value

Annual Sales: $2.59 million
Price / Sales: 0.00
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.21) per share
Price / Book: N/A

Miscellaneous

Outstanding Shares: 90,760,000
Free Float: 81,857,000
Market Cap: $726,000.00
Optionable: Optionable
Beta: 1.63

Social Links

20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

Dr. Lawrence E. Bloch J.D. (Age 57)
M.D., Treasurer
Comp: $513.61k
Mr. Seth A. Tasker J.D. (Age 44)
CEO, Sr. VP, Gen. Counsel & Sec.

Key Competitors

View All Competitors

Insiders

Adelene Q Perkins
Sold 410,196 shares
Total: $28,713.72 ($0.07/share)

View All Insider Transactions

INFI Stock Analysis - Frequently Asked Questions

Should I buy or sell Infinity Pharmaceuticals stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Infinity Pharmaceuticals in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" INFI shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in INFI, but not buy additional shares or sell existing shares.
View INFI analyst ratings or view top-rated stocks.
How were Infinity Pharmaceuticals' earnings last quarter?: Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) issued its quarterly earnings results on Tuesday, November, 2nd. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.14) by $0.02. The biotechnology company earned $0.43 million during the quarter, compared to analysts' expectations of $0.45 million. During the same quarter in the previous year, the firm earned ($0.16) EPS.
What is Adelene Q. Perkins' approval rating as Infinity Pharmaceuticals' CEO?: 10 employees have rated Infinity Pharmaceuticals Chief Executive Officer Adelene Q. Perkins on Glassdoor.com. Adelene Q. Perkins has an approval rating of 100% among the company's employees. This puts Adelene Q. Perkins in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Infinity Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Infinity Pharmaceuticals investors own include Continental Resources (CLR), Rex Energy (REXX), Aerie Pharmaceuticals (AERI), Gilead Sciences (GILD), OPKO Health (OPK), AVEO Pharmaceuticals (AVEO), ImmunoGen (IMGN), Inovio Pharmaceuticals (INO), Novavax (NVAX) and Celldex Therapeutics (CLDX).
Who are Infinity Pharmaceuticals' major shareholders?: Infinity Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Adelene Q Perkins and Bvf Partners L P/Il.
View institutional ownership trends.

This page (NASDAQ:INFI) was last updated on 12/5/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Infinity Pharmaceuticals Stock Price, News & Analysis (NASDAQ:INFI)

About Infinity Pharmaceuticals Stock (NASDAQ:INFI)

INFI Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders

INFI Stock Analysis - Frequently Asked Questions

About MarketBeat

Popular Tools

Financial Calendars

Terms & Info